- Home
- CODX vs BCDA Comparison
CODX vs BCDA Comparison
Compare CODX & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CODX
- BCDA
- Stock Information
- Founded
- CODX 2013
- BCDA N/A
- Country
- CODX United States
- BCDA United States
- Employees
- CODX N/A
- BCDA N/A
- Industry
- CODX Medical/Dental Instruments
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- CODX Health Care
- BCDA Health Care
- Exchange
- CODX Nasdaq
- BCDA Nasdaq
- Market Cap
- CODX 15.6M
- BCDA 13.7M
- IPO Year
- CODX 2017
- BCDA N/A
- Fundamental
- Price
- CODX $0.33
- BCDA $1.24
- Analyst Decision
- CODX Buy
- BCDA Strong Buy
- Analyst Count
- CODX 2
- BCDA 1
- Target Price
- CODX $2.00
- BCDA $25.00
- AVG Volume (30 Days)
- CODX 61.3M
- BCDA 114.5K
- Earning Date
- CODX 11-13-2025
- BCDA 11-12-2025
- Dividend Yield
- CODX N/A
- BCDA N/A
- EPS Growth
- CODX N/A
- BCDA N/A
- EPS
- CODX N/A
- BCDA N/A
- Revenue
- CODX $507,892.00
- BCDA N/A
- Revenue This Year
- CODX N/A
- BCDA N/A
- Revenue Next Year
- CODX $31.58
- BCDA N/A
- P/E Ratio
- CODX N/A
- BCDA N/A
- Revenue Growth
- CODX N/A
- BCDA N/A
- 52 Week Low
- CODX $0.23
- BCDA $1.00
- 52 Week High
- CODX $1.55
- BCDA $3.20
- Technical
- Relative Strength Index (RSI)
- CODX 44.98
- BCDA 38.61
- Support Level
- CODX $0.38
- BCDA $1.25
- Resistance Level
- CODX $0.40
- BCDA $1.34
- Average True Range (ATR)
- CODX 0.07
- BCDA 0.08
- MACD
- CODX -0.02
- BCDA -0.00
- Stochastic Oscillator
- CODX 2.26
- BCDA 4.30
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).